Exodus Point Capital Management, LP Sage Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

$14.7 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$18.62 - $26.95 $1.34 Million - $1.95 Million	72,234 Added 240.21%	102,305 $1.92 Million
Q3 2023 Nov 09, 2023	BUY	$16.75 - $48.98 $503,689 - $1.47 Million	30,071 New	30,071 $619,000
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $1.77 Million - $2.4 Million	-55,117 Reduced 79.61%	14,116 $538,000
Q3 2022 Nov 10, 2022	SELL	$32.28 - $43.27 $2.38 Million - $3.19 Million	-73,722 Reduced 51.57%	69,233 $2.71 Million
Q2 2022 Aug 19, 2022	SELL	$27.52 - $37.99 $769,321 - $1.06 Million	-27,955 Reduced 16.36%	142,955 $4.62 Million
Q1 2022 May 13, 2022	BUY	$30.71 - $45.71 $5.25 Million - $7.81 Million	170,910 New	170,910 $5.66 Million
Q4 2021 Feb 11, 2022	SELL	$37.06 - $47.11 $1.93 Million - $2.46 Million	-52,134 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $867,764 - $1.24 Million	21,554 Added 70.48%	52,134 $2.31 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $1.45 Million - $2.1 Million	26,433 Added 637.4%	30,580 $1.74 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $123,778 - $169,523	1,752 Added 73.15%	4,147 $310,000
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $1.22 Million - $1.86 Million	-20,915 Reduced 89.73%	2,395 $207,000
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $595,397 - $904,026	-14,476 Reduced 38.31%	23,310 $1.43 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $980,546 - $1.63 Million	37,786 New	37,786 $1.57 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $477,266 - $646,243	-3,402 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $537,005 - $622,872	3,402 New	3,402 $623,000

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $414M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.

Account